1. Search Result
Search Result
Results for "

helicase

" in MedChemExpress (MCE) Product Catalog:

117

Inhibitors & Agonists

2

Fluorescent Dye

1

Peptides

11

Natural
Products

28

Recombinant Proteins

1

Isotope-Labeled Compounds

35

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-E70379

    DNA/RNA Synthesis Others
    Tte UvrD Helicase is a thermostable UvrD helicase initially isolated from Thermoanaerobacter tengcongensis. Tte UvrD Helicase can unwind DNA duplexes with 3’ or 5’ single-stranded DNA tails, and DNA substrates with blunt ends .
    Tte UvrD Helicase
  • HY-148740

    DNA/RNA Synthesis Cancer
    Werner syndrome RecQ helicase-IN-3 is a potent and orally active werner syndrome recQ helicase (WRN) inhibitor with an IC50 value of 0.06 µM. Werner syndrome RecQ helicase-IN-3 shows antiproliferative activity. Werner syndrome RecQ helicase-IN-3 shows anticancer activity .
    Werner syndrome RecQ helicase-IN-3
  • HY-148741

    DNA/RNA Synthesis Cancer
    Werner syndrome RecQ helicase-IN-4 is a potent and orally active werner syndrome recQ helicase (WRN) inhibitor with an IC50 value of 0.06 µM. Werner syndrome RecQ helicase-IN-4 shows antiproliferative activity. Werner syndrome RecQ helicase-IN-4 shows anticancer activity .
    Werner syndrome RecQ helicase-IN-4
  • HY-163529

    HSV Infection
    HN0037 is a selective and orally active helicase-primase inhibitor. HN0037 inhibits HSV replication by targeting the viral helicase-primase enzyme complex .
    HN0037
  • HY-148700

    DNA/RNA Synthesis Cancer
    Werner syndrome RecQ helicase-IN-2 (example 57) is a potent Werner syndrome RecQ DNA helicase enzyme (WRN) inhibitor and can be used in cancer research .
    Werner syndrome RecQ helicase-IN-2
  • HY-163529A

    HSV Infection
    (S)-HN0037 is the (S)-isomer of HN0037 (HY-163529), a selective and orally active helicase-primase inhibitor that inhibits HSV replication by targeting the viral helicase-primase enzyme complex .
    (S)-HN0037
  • HY-148699
    HRO761
    3 Publications Verification

    Werner syndrome RecQ helicase-IN-1

    DNA/RNA Synthesis Cancer
    HRO761 (Werner syndrome RecQ helicase-IN-1) (example 42) is a potent Werner syndrome RecQ DNA helicase enzyme (WRN) inhibitor and can be used in cancer research .
    HRO761
  • HY-128712

    DNA/RNA Synthesis Cancer
    NCGC00029283 is a werner syndrome helicase-nuclease (WRN) helicase inhibitor with IC50s of 2.3 μM, 12.5 μM, and 3.4 μM for WRN, BLM and FANCJ helicase, respectively .
    NCGC00029283
  • HY-168592

    DNA/RNA Synthesis Cancer
    WRN inhibitor 12 (compound 5) is an inhibitor of WRN helicase .
    WRN inhibitor 12
  • HY-164852

    DNA/RNA Synthesis Others
    WRN inhibitor 13 is a WRN helicase inhibitor with a pIC50 of 6-7 .
    WRN inhibitor 13
  • HY-146987

    SARS-CoV Infection
    FWM-3 is a potent SARS-CoV-2 NSP13 helicase inhibitor .
    FWM-3
  • HY-137820

    DNA/RNA Synthesis Others
    Brr2-IN-3 is a potent and selective Brr2 helicase allosteric Inhibitor. Brr2-IN-3 inhibits helicase activity in dose-dependent manner with an IC50 value of 1.3 μM .
    Brr2-IN-3
  • HY-161151

    DNA/RNA Synthesis Apoptosis Cancer
    Frangulin B (Compd 11g), a potent anticancer agent, is a potential pan RecQ helicase inhibitor . Frangulin B (Compd 11g) induces apoptosis in both HCT-116 and MDA-MB-231 cell lines, but also causes an G2/M phase cell cycle arrest in HCT-116 cells .
    RecQ helicase-IN-1
  • HY-157610

    DNA/RNA Synthesis Cancer
    DHX9-IN-14 (161) is a RNA helicase DHX9 inhibitor, with an EC50 of 3.4 μM in DHX9 cellular target engagement. Used in cancer research .
    DHX9-IN-14
  • HY-157607

    DNA/RNA Synthesis Cancer
    DHX9-IN-15 (287) is a RNA helicase DHX9 inhibitor, with an EC50 of 0.232 μM in DHX9 cellular target engagement. Used in cancer research .
    DHX9-IN-15
  • HY-157609

    DNA/RNA Synthesis Cancer
    DHX9-IN-12 (83) is a RNA helicase DHX9 inhibitor, with an EC50 of 0.917 μM in DHX9 cellular target engagement. Used in cancer research .
    DHX9-IN-12
  • HY-157612

    DNA/RNA Synthesis Cancer
    DHX9-IN-16 (208) is a RNA helicase DHX9 inhibitor, with an EC50 of 0.125 μM in DHX9 cellular target engagement. Used in cancer research .
    DHX9-IN-16
  • HY-157603

    DNA/RNA Synthesis Cancer
    DHX9-IN-7 (550) is a RNA helicase DHX9 inhibitor, with an EC50 of 0.105 μM in DHX9 cellular target engagement. Used in cancer research .
    DHX9-IN-7
  • HY-157606

    DNA/RNA Synthesis Cancer
    DHX9-IN-13 (389) is a RNA helicase DHX9 inhibitor, with an EC50 of 3.4 μM in DHX9 cellular target engagement. Used in cancer research .
    DHX9-IN-13
  • HY-157604

    DNA/RNA Synthesis Cancer
    DHX9-IN-9 (509) is a RNA helicase DHX9 inhibitor, with an EC50 of 0.0177 μM in DHX9 cellular target engagement. Used in cancer research .
    DHX9-IN-9
  • HY-157605

    DNA/RNA Synthesis Cancer
    DHX9-IN-11 (469) is a RNA helicase DHX9 inhibitor, with an EC50 of 0.0838 μM in DHX9 cellular target engagement. Used in cancer research .
    DHX9-IN-11
  • HY-157608

    DNA/RNA Synthesis Cancer
    DHX9-IN-10 (49) is a RNA helicase DHX9 inhibitor, with an EC50 of 9.04 μM in DHX9 cellular target engagement. Used in cancer research .
    DHX9-IN-10
  • HY-157611

    DNA/RNA Synthesis Cancer
    DHX9-IN-17 (186) is a RNA helicase DHX9 inhibitor, with an EC50 of 0.161 μM in DHX9 cellular target engagement. Used in cancer research .
    DHX9-IN-17
  • HY-110185
    NSC 617145
    2 Publications Verification

    DNA/RNA Synthesis Cancer
    NSC 617145 is a selective werner syndrome helicase (WRN) helicase inhibitor with an IC50 value of 230 nM. NSC 617145 inhibits WRN ATPase, and induces double-strand breaks (DSB) and chromosomal abnormalities. NSC 617145 shows selective for WRN over BLM, FANCJ, ChlR1, RecQ, and UvrD helicases .
    NSC 617145
  • HY-157602

    DNA/RNA Synthesis Cancer
    DHX9-IN-8 (Compound 6) is a RNA helicase DHX9 inhibitor, with an EC50 of 3.4 μM in DHX9 cellular target engagement. Used in cancer research .
    DHX9-IN-8
  • HY-106305

    CI 958

    DNA/RNA Synthesis Cancer
    Ledoxantrone (CI 958) is a DNA helicases inhibitor with an IC50 of 0.17 μM. Ledoxantrone can be used in the study of prostate cancer .
    Ledoxantrone
  • HY-106305A

    CI 958 trihydrochloride

    DNA/RNA Synthesis Cancer
    Ledoxantrone (CI 958) trihydrochloride is a DNA helicases inhibitor with an IC50 of 0.17 μM. Ledoxantrone trihydrochloride can be used in the study of prostate cancer .
    Ledoxantrone trihydrochloride
  • HY-161916

    DNA/RNA Synthesis Cancer
    Polθ-IN-4 (Example 1) is a DNA polymerase theta (Polθ) inhibitor that inhibits Polθ activity by targeting its ATP-dependent helicase domain. Polθ-IN-4 can be utilized in cancer research .
    Polθ-IN-4
  • HY-174217

    DNA/RNA Synthesis Cancer
    WRN-IN-19 (Compound (S)-27) is a covalent WRN helicase inhibitor, with pIC50 (0 h/4 h) = 5.4/7.5 in the DNA-unwinding 5 endpoint assays. WRN-IN-19 shows synthetic lethality in MSI-H (high microsatellite instability) cancer cells .
    WRN-IN-19
  • HY-161386

    DNA/RNA Synthesis Cancer
    WRN inhibitor 7 (Compound h6) is a WRN inhibitor. WRN inhibitor 7 effectively inhibits WRN's helicase and ATPase activity (IC50: 9.8 μM and 15.8 μM respectively). WRN inhibitor 7 can be used for research of microsatellite instable (MSI) cancers .
    WRN inhibitor 7
  • HY-150279
    PolQi2
    2 Publications Verification

    DNA/RNA Synthesis Others
    PolQi2 is a PolΘ inhibitor that targets and inhibits alt-EJ (alternative end-joining) repair by inhibiting the helicase domain at the N-terminus of PolΘ. PolQi2 enhances the precision and integration efficiency of gene editing at different loci and in various cell lines. Furthermore, the combined use of PolQi2 with DNA-PK inhibitors reduces the off-target effects of Cas9. PolQi2 can be used in gene editing research .
    PolQi2
  • HY-163941

    DNA/RNA Synthesis Cancer
    GSK_WRN2 is a potent and selective covalent WRN helicase inhibitor that suppresses replication stress caused by DNA (TA)n dinucleotide repeat expansions. GSK_WRN2 can be used to study microsatellite instability (MSI) cancers .
    GSK_WRN2
  • HY-152259

    TMV Infection
    TMV-IN-4 (compound 3) is a tobacco mosaic virus (TMV) inhibitor that effectively induces resistance and enhances plant tolerance to TMV infection by interacting with TMV helicase. TMV-IN-4 enhances peroxidase and superoxide dismutase activity, thereby increasing resistance to TMV in tobacco .
    TMV-IN-4
  • HY-156579

    DNA/RNA Synthesis Cancer
    WRN inhibitor 3 (example 110), a cyclic vinyl sulfone compound, is a Wemer Syndrome ATP dependent helicase enzyme (WRN) inhibitor. WRN inhibitor 3 can be used for the research of cancer .
    WRN inhibitor 3
  • HY-156580

    DNA/RNA Synthesis Cancer
    WRN inhibitor 4 (example 107), a cyclic vinyl sulfone compound, is a Wemer Syndrome ATP dependent helicase enzyme (WRN) inhibitor. WRN inhibitor 4 can be used for the research of cancer .
    WRN inhibitor 4
  • HY-156418

    DNA/RNA Synthesis Cancer
    KY386 is a potent, selective inhibitor of DHX33 helicase, with the IC50 of 19 nM. KY386 inhibits U251-MG cells (DHX33-overexpressing cancer cell strain) with IC50 of 20 nM.and shows potent anti-cancer activity and moderate metabolic stability .
    KY386
  • HY-169422

    IDE275

    DNA/RNA Synthesis Cancer
    GSK4418959 (IDE275) is a non-covalent, reversible, selective and orally active WRN helicase inhibitor. GSK4418959 inhibits ATPase and DNA unwinding functions in an ATP-competitive manner. GSK4418959 can be used for the study of microsatellite instability-high (MSI-H) cancer .
    GSK4418959
  • HY-15303B
    Pritelivir mesylate hydrate
    5+ Cited Publications

    AIC316 mesylate hydrate; BAY 57-1293 mesylate hydrate

    HSV Infection
    Pritelivir mesylate hydrate (BAY 57-1293 mesylate hydrate), an inhibitor of the viral helicase-primase complex, exhibits antiviral activity in vitro and in animal models of herpes simplex virus (HSV) infection. Pritelivir mesylate hydrate is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) with the IC50 of 0.02 μM against HSV1-2 .
    Pritelivir mesylate hydrate
  • HY-15303
    Pritelivir
    5+ Cited Publications

    AIC316; BAY 57-1293

    HSV Infection
    Pritelivir (AIC316), an inhibitor of the viral helicase-primase complex, exhibits antiviral activity in vitro and in animal models of herpes simplex virus (HSV) infection. Pritelivir is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) with the IC50 of 0.02 μM against HSV1-2 .
    Pritelivir
  • HY-15303A
    Pritelivir mesylate
    5+ Cited Publications

    AIC316 mesylate; BAY 57-1293 mesylate

    HSV Infection
    Pritelivir mesylate (BAY 57-1293 mesylate), an inhibitor of the viral helicase-primase complex, exhibits antiviral activity in vitro and in animal models of herpes simplex virus (HSV) infection. Pritelivir mesylate is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) with the IC50 of 0.02 μM against HSV1-2 .
    Pritelivir mesylate
  • HY-162471

    DNA/RNA Synthesis ATM/ATR Cancer
    GSK_WRN3 is selective WRN helicase inhibitor (pIC50 = 8.6). SK_WRN3 can selectively inhibit the growth of microsatellite unstable (MSI) cancer cells, induce DNA damage, and cause cell cycle arrest. GSK_WRN3 has anti-tumor activity .
    GSK_WRN3
  • HY-169422A

    IDE275 (enantiomer)

    DNA/RNA Synthesis Cancer
    GSK4418959 enantiomer is an enantiomer of GSK4418959 (HY-169422). GSK4418959 (IDE275) is a non-covalent, reversible, selective and orally active WRN helicase inhibitor. GSK4418959 inhibits ATPase and DNA unwinding functions in an ATP-competitive manner. GSK4418959 can be used for the study of microsatellite instability-high (MSI-H) cancer .
    GSK4418959 (enantiomer)
  • HY-156581

    DNA/RNA Synthesis Cancer
    WRN inhibitor 5, a cyclic vinyl sulfone compound, is a Wemer Syndrome ATP dependent helicase enzyme (WRN) inhibitor. WRN inhibitor 5 can be used for the research of cancer, including cancers characterized by microsatellite instability (MSI) and/or defective DNA mismatch repair system (dMMR) .
    WRN inhibitor 5
  • HY-15303AR

    HSV Infection
    Pritelivir (mesylate) (Standard) is the analytical standard of Pritelivir (mesylate). This product is intended for research and analytical applications. Pritelivir mesylate (BAY 57-1293 mesylate), an inhibitor of the viral helicase-primase complex, exhibits antiviral activity in vitro and in animal models of herpes simplex virus (HSV) infection. Pritelivir mesylate is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) with the IC50 of 0.02 μM against HSV1-2 .
    Pritelivir mesylate (Standard)
  • HY-15303R

    HSV Infection
    Pritelivir (Standard) is the analytical standard of Pritelivir. This product is intended for research and analytical applications. Pritelivir (AIC316), an inhibitor of the viral helicase-primase complex, exhibits antiviral activity in vitro and in animal models of herpes simplex virus (HSV) infection. Pritelivir is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) with the IC50 of 0.02 μM against HSV1-2 .
    Pritelivir (Standard)
  • HY-12342
    ML216
    5+ Cited Publications

    CID-49852229

    DNA/RNA Synthesis Cancer
    ML216 (CID-49852229) is a potent, selective and cell permeable inhibitor of the DNA unwinding activity of BLM helicase with IC50s of 2.98 μM and 0.97 μM for BLM full-length and BLM 636-1298, respectively. ML216 inhibits ssDNA-dependent ATPase activity of BLM with a Ki of 1.76 μM. Antitumor avtivity .
    ML216
  • HY-100455
    RK-33
    4 Publications Verification

    DNA/RNA Synthesis SARS-CoV Cancer
    RK-33 is an RNA helicase inhibitor against DDX3, and inhibits its helicase activity.
    RK-33
  • HY-175750

    DNA/RNA Synthesis Cancer
    MOMA-341 is a selective Werner RecQ like helicase (WRN) inhibitor. MOMA-341 binds to WRN at cysteine 727 through an allosteric and ATP-competitive binding mechanism. MOMA-341 induces DNA damage, cell death, and tumor regressions in mismatch-repair deficient (dMMR)/microsatellite instability high (MSI-H) mice model. MOMA-341 has antitumor activity, promising for advanced and metastatic solid tumors research .
    MOMA-341
  • HY-162707

    Others Infection
    RA-0002323-01 is an antiviral agent targeting viral helicase and is an active compound from Heli-SMACC, a collection of small molecules targeting helicase .
    RA-0002323-01
  • HY-162146

    Filovirus DNA/RNA Synthesis Infection
    NS3-IN-1 (compound 302) is a potent helicase (NS3) inhibitor. NS3-IN-1 shows an potent inhibitor for yellow fever helicase .
    NS3-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: